scholarly journals Therapy of Multiple Myeloma and Myeloma-Related Kidney Disease

2017 ◽  
Vol 2 (1) ◽  
pp. 1-14
Author(s):  
Ota Fuchs
Keyword(s):  
Multiple Myeloma ◽  
Kidney Disease

scholarly journals Severe hyperphosphatemia in a patient with chronic kidney disease and multiple myeloma-to strengthen the case toward renal replacement therapy?

2013 ◽  
Vol 1 (2) ◽  
pp. 72-74 ◽  
Author(s):  
Joerg Latus ◽  
Elisabeth Höring ◽  
Matthias Voehringer ◽  
Dieter Ratge ◽  
M. Dominik Alscher ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Multiple Myeloma ◽  
Renal Replacement Therapy ◽  
Kidney Disease ◽  
Replacement Therapy

scholarly journals Mandibular Osteonecrosis Induced by Bisphosphonates in a Carrier of Chronicle Kidney Disease

2018 ◽  
Vol 4 (1) ◽  
pp. 1119-1125
Author(s):  
Kaohana Da Silva ◽  
Greison De Oliveira ◽  
Eleonor Garbin-Júnior ◽  
Natasha Magro-Érnica ◽  
Geraldo Griza ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Multiple Myeloma ◽  
Renal Function ◽  
Bone Resorption ◽  
Kidney Disease ◽  
Impaired Renal Function ◽  
Clinical Case ◽  
Treatment Protocol ◽  
Inorganic Pyrophosphate ◽  
Jaw Osteonecrosis

The bisphosphonates are synthetic substances of inorganic pyrophosphate that have been the basis of treatment of patients with osteolytic diseases, such as multiple myeloma, malignant hypercalcemia, Paget's disease, or patients with bone metastases. Its main pharmacological effect is inhibition of bone resorption caused by osteoclasts, which have a reduced function. Their adverse effects are infrequent but include pyrexia, impaired renal function, hypocalcemia, and more recently, maxillo-mandibular ostenecrose induced bofosfonatos. In this report we describe a clinical case of jaw osteonecrosis induced by bisphosphonates in patient with chronic kidney disease and the treatment protocol performed.

Chronic kidney disease stage 5 as the prognostic complement of International Staging System for multiple myeloma

2011 ◽  
Vol 88 (2) ◽  
pp. 159-166 ◽  
Author(s):  
Liang-Tsai Hsiao ◽  
Ching-Fen Yang ◽  
Sheng-Hsiang Yang ◽  
Jyh-Pyng Gau ◽  
Yuan-Bin Yu ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Multiple Myeloma ◽  
Kidney Disease ◽  
Chronic Kidney Disease Stage ◽  
Staging System ◽  
Disease Stage ◽  
International Staging System

P0868ZONULIN AS A THERAPEUTIC POTENTIAL BIOMARKER OF ANEMIA IN PATIENTS WITH MULTIPLE MYELOMA AND CHRONIC KIDNEY DISEASE

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Karolina Woziwodzka ◽  
Jolanta Malyszko ◽  
Małgorzata Banaszkiewicz ◽  
Ewa Koc- Żorawska ◽  
Paulina Dumnicka ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Multiple Myeloma ◽  
Kidney Disease ◽  
Iron Status ◽  
P Value ◽  
Blood Collection ◽  
Serum Concentrations ◽  
Monoclonal Protein ◽  
Blood Hemoglobin ◽  
Potential Biomarker

Abstract Background and Aims Zonulin is a haptoglobin 2 precursor, that regulates the intestinal permeability. As a double-chain form it takes part in scavenging haemoglobin. Chronic inflammation is common complication of chronic kidney disease which affects iron metabolism. The most frequent manifestation of multiple myeloma is anaemia in up to 73% of patients. Serum concentrations of zonulin are associated with inflammation process, age, kidney failure and iron status and anaemia. The aim of the study was to analyse zonulin as a marker of anaemia in MM patients and investigate its relationship with acclaimed parameters of renal failure, inflammation, bone metabolism and stages of MM. Method The studied group of seventy-three patients with MM (67 symptomatic, 6 smoldering) included 35 women and 38 man, with mean age 69 ± 10 years. Median (IQR) of time from initial MM diagnosis was 36 (17; 69) months. Forty patients were in ISS stage 1, 15 in stage 2, and 12 in stage 3 at the time of blood collection. Remission of MM was diagnosed in 52 patients and stable or progressive disease in 21. Twenty-six patients had eGFR <60 ml/min/1.73 m2. The examined parameters included creatinine, urea, serum monoclonal protein, albumin, ferritin, blood hemoglobin and NT-proBNP. The association between zonulin, markers of MM stages and renal and bone markers were determined by the Pearson's test and multivariate stepwise regression analysis. The p-value <0.05 was considered statistically significant. Results Median (IQR) serum zonulin in the studied group was 23.9 (19.9; 27.4) ng/ml. There were no differences in zonulin concentrations between patients with smoldering versus symptomatic MM (p=0.4), with ISS 1 to 3 (p=0.7), with remission versus stable or progressive MM (p=0.9), or with eGFR <60 ml/min/1.73 m2 versus those with higher eGFR (p=0.6). Also, zonulin did not differ between subjects with and without anemia (Hb< the lower reference limit) (p=0.4). In whole studied group, significant correlations were observed between zonulin and serum albumin (R=0.30; p=0.009), creatinine (R=-0.28; p=0.018), eGFR (R=0.26; p=0.025), ferritin (R=0.34; p=0.013), NT-proBNP (R=-0.32; p=0.006). Moreover, in patients with symptomatic MM, zonulin correlated with monoclonal protein in serum (R=-0.29; p=0.046), blood hemoglobin (R=0.27; p=0.027), and age (R=-0.24; p=0.044). In multiple regression, serum concentrations of monoclonal protein (beta=-0.48 ± 0.16; p=0.006) and ferritin (beta=0.34 ± 0.14; p=0.023) as well as ISS stage 3 (beta=0.40 ± 0.18; p=0.034) were identified as independent predictors of zonulin concentrations. Conclusion Zonulin as a biomarker may promote diagnosis of etiology and management of MM-associated anaemia, which can contribute to biomarker-targeted therapeutic interventions. Early treatment may result in improved life expectancy in patients with MM and increase their quality of life.

scholarly journals The renal range of the κ/λ sFLC ratio: best strategy to evaluate multiple myeloma in patients with chronic kidney disease

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Alícia Molina-Andújar ◽  
Pau Robles ◽  
Maria T. Cibeira ◽  
Enrique Montagud-Marrahi ◽  
Elena Guillen ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Multiple Myeloma ◽  
Kidney Disease

scholarly journals SUN-131 DIAGNOSTIC, THERAPEUTIC AND EVOLUTIONARY FEATURES OF KIDNEY DISEASE IN MULTIPLE MYELOMA

2020 ◽  
Vol 5 (3) ◽  
pp. S256
Author(s):  
N. BRAIEK ◽  
S. Barbouch ◽  
S. Fattoum ◽  
E. Faleh ◽  
M. Hajji ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Kidney Disease ◽  
Evolutionary Features
Sign in / Sign up

Export Citation Format

Share Document